In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 384, Issue 3, 2011, Pages 319-329

  Yamazaki, Takanobu ^a   Muraki, Yukiko ^a   Anraku, Tsuyoshi ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antimuscarinic agent; Bladder capacity. Cystometry; Bladder selectivity; Imidafenacin; Overactive bladder (OAB)

Indexed keywords

CARBACHOL; IMIDAFENACIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE; URETHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CAPACITY; BLADDER CONTRACTION; BLADDER PRESSURE; BRADYCARDIA; CHORDA TYMPANI; CONTROLLED STUDY; CYSTOMETRY; DRUG EFFICACY; DRUG SELECTIVITY; ELECTROSTIMULATION; EXPERIMENTAL RAT; HEART RATE; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; MICTURITION REFLEX; NONHUMAN; OVERACTIVE BLADDER; PRESSORECEPTOR REFLEX; RAT; RESIDUAL VOLUME; SALIVATION; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE;

ANIMALS; BAROREFLEX; IMIDAZOLES; MALE; MOLECULAR STRUCTURE; MUSCARINIC ANTAGONISTS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; RATS; RATS, SPRAGUE-DAWLEY; SALIVA; SALIVARY GLANDS; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 80054945654     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0675-1     Document Type: Article

References (45)

1. Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987-1006 (Pubitemid 47537675)
2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A, Standardisation Sub-committee of the International Continence Society (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167-178 (Pubitemid 34195211)
3. Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565-578 (Pubitemid 43993048)
4. Akino H, Namiki M, Suzuki K, Fuse H, Yokoyama O (2009) Treatment satisfaction with antimuscarinics: which type of drug is desirable to patients with OAB? J Urol 181(Suppl):675
5. Andersson KE (1999) Advances in the pharmacological control of the bladder. Exp Physiol 84:195-213
6. Andersson KE, Olshansky B (2007) Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int 100:1007-1014 (Pubitemid 47537647)
7. Andersson KE, Yoshida M (2003) Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol 43:1-5 (Pubitemid 36134308)
8. Chapple CR, Nilvebrant L (2002) Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. Drugs R D 3:75-81 (Pubitemid 37062606)
9. El-Mas MM, Afify EA, Omar AG, Sharabi FM (2002) Cyclosporine adversely affects baroreflexes via inhibition of testosterone modulation of cardiac vagal control. J Pharmacol Exp Ther 301:346-354 (Pubitemid 34250313)
10. Finney SM, Andersson KE, Gillespie JI, Stewart LH (2006) Antimuscar-inic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 98:503-507 (Pubitemid 44185865)
11. Gillespie JI, van Koeveringe GA, de Wachter SG, de Vente J (2009) On the origins of the sensory output from the bladder: the concept of afferent noise. BJU Int 103:1324-1333
12. Hedlund P, Streng T, Lee T, Andersson KE (2007) Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. J Urol 178:326-331 (Pubitemid 46898458)
13. Hegde SS (2006) Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147(Suppl 2):S80-S87 (Pubitemid 43237576)
14. Homma Y, Yamaguchi O, Imidafenacin Study Group (2009) A randomized, double-blind, placebo-and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 16:499-506
15. Igawa Y, Zhang X, Nishizawa O, Umeda M, Iwata A, Taketo MM, Manabe T, Matsui M, Andersson KE (2004) Cystometric findings in mice lacking muscarinic M2 or M3 receptors. J Urol 172:2460-2464 (Pubitemid 39507553)
16. Iijima K, De Wachter S, Wyndaele JJ (2007) Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 52:842-847
17. Ikeda K, Kobayashi S, Suzuki M, Miyata K, Takeuchi M, Yamada T, Honda K (2002) M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 366:97-103 (Pubitemid 34762267)
18. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 65:238-242 (Pubitemid 40248004)
19. Kobayashi F, Yageta Y, Segawa M, Matsuzawa S (2007a) Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 57:92-100 (Pubitemid 46383949)
20. Kobayashi F, Yageta Y, Yamazaki T, Wakabayashi E, Inoue M, Segawa M, Matsuzawa S (2007b) Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittelforschung 57:147-154 (Pubitemid 46580657)
21. La Rovere MT, Pinna GD, Hohnloser SH, Marcus FI, Mortara A, Nohara R, Bigger JT Jr, Camm AJ, Schwartz PJ, Investigators ATRAMI, Tone A, Infarcton Reflexes After Myocardial (2001) Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 103:2072-2077 (Pubitemid 32373010)
22. Li M, Johnson CP, Adams MB, Sarna SK (2002) Cholinergic and nitrergic regulation of in vivo giant migrating contractions in rat colon. Am J Physiol Gastrointest Liver Physiol 283:G544-G552 (Pubitemid 34920340)
23. Mansfield KJ (2010) Muscarinic receptor antagonists, the overactive bladder and efficacy against urinary urgency. Clin Med Insight: Ther 2:471-480
24. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E (2005) Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 144:1089-1099 (Pubitemid 40593007)
25. McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, Armstrong SR, Steinfeld T, Hughes AD, Wilson RD, Jasper JR, Mammen M, Hegde SS (2009) Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist. Eur J Pharmacol 605:145-152
26. Nomura N, Kaneko S, Hamakawa T, Nagai M, Iriki M (1989) Effects of propiverine hydrochloride (P-4) and its metabolites on urinary bladder function in anesthetized rats. Folia Pharmacol Jpn 94:173-180 (Pubitemid 19217497)
27. OhnoT,NakadeS,NakayamaK, Kitagawa J,UedaS,MiyabeH,Masuda Y, Miyata Y (2008) Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Br J Clin Pharmacol 65:197-202 (Pubitemid 351171265)
28. Ohtake A, Ukai M, Hatanaka T, Kobayashi S, Ikeda K, Sato S, Miyata K, Sasamata M (2004) In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 492:243-250 (Pubitemid 38721378)
29. Ohtake A, Sato S, Ikeda K, Sasamata M, Miyata K (2006) Pharmacological and clinical profile of solifenacin succinate (Vesicare) developed as a new therapeutic agent for overactive bladder. Folia Pharmacol Jpn 128:425-432 (Pubitemid 351420652)
30. Ohtake A, Saitoh C, Yuyama H, Ukai M, Okutsu H, Noguchi Y, Hatanaka T, Suzuki M, Sato S, Sasamata M, Miyata K (2007) Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 30:54-58 (Pubitemid 46066319)
31. Oki T, Yamada S, Tohma A, Kimura R (2001) Muscarinic receptor binding characteristics in rat tissues after oral administration of oxybutynin and propiverine. Biol Pharm Bull 24:491-495 (Pubitemid 32499473)
32. Oki T, Sato S, Miyata K, Yamada S (2005) Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Br J Pharmacol 145:219-227 (Pubitemid 40756526)
33. Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS (2008) Parasym-pathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 118:863-871
34. Sinha S, Gupta S, Malhotr S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A (2010) AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol 160:1119-1127
35. Sugisawa M, Takai N (1991) The role of substance P in parasympathetic nerve-induced secretion in the rat submandibular gland. J Osaka Dent Univ 25:51-62
36. Suzuki M, Ohtake A, Yoshino T, Yuyama H, Hayashi A, Ukai M, Okutsu H, Noguchi Y, Sato S, Sasamata M (2005) Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats. Eur J Pharmacol 512:61-66 (Pubitemid 40462364)
37. Takagi-Matsumoto H, Ng B, Tsukimi Y, Tajimi M (2004) Effects of NSAIDs on bladder function in normal and cystitis rats: a comparison study of aspirin, indomethacin, and ketoprofen. J Pharmacol Sci 95:458-465 (Pubitemid 39237475)
38. Wada Y, Yoshida M, Kitani K, Kikukawa H, Ichinose A, Takahashi W, Gotoh S, Inadome A, Machida J, Ueda S (1995) Comparison of the effects of various anticholinergic drugs on human isolated urinary bladder. Arch Int Pharmacodyn Ther 330:76-89 (Pubitemid 26018700)
39. Wess J, Angeli P, Melchiorre C, Moser U, Mutschler E, Lambrecht G (1988) Methoctramine selectively blocks cardiac muscarinic M2 receptors in vivo. Naunyn Schmiedebergs Arch Pharmacol 338:246-249
40. Yamada S, Seki M, Ogoda M, Fukata A, Nakamura M, Ito Y (2011) Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafe-nacin, to treat overactive bladder. J Pharmacol Exp Ther 336:365-371
41. Yamaguchi O (2010) Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodynam 29:112-11 5
42. Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H (2005) Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol 174:2032-2036 (Pubitemid 41547018)
43. Yokoyama O, Tanaka I, Kusukawa N, Yamauchi H, Ito H, Aoki Y, Oyama N, Miwa Y, Akino H (2011) Antimuscarinics suppress adenosine triphosphate and prostaglandin E2 release from urothelium with potential improvement in detrusor overactivity in rats with cerebral infarction. J Urol 185:2392-2397
44. Yoshida M, Masunaga K, Nagata T, Yono M, Homma Y (2010) The forefront for novel therapeutic agents based on the pathophysi-ology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder. J Pharmacol Sci 112:128-134
45. Zinner N, Tuttle J, Marks L (2005) Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 23:248-252